# US 2018/0021276 A1 · Bezafibrate for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021276 A1
- Document ID: US20180021276A1
- Status: Published application
- Kind: A1
- Application number: 15/653,814
- Filed: 2017-07-19
- Published: 2018-01-25
- Earliest claimed: 2016-07-20
- Assignees: Cipla Limited
- Applicants: Cipla Limited
- Inventors: Geena Malhotra; Kalpana Joshi; Jeevan Ghosalkar
- Web page: https://patentgrep.com/patent/US20180021276A1

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4858: {Organic compounds}
- A61K 31/195: having an amino group
- A61K 31/404: Indoles, e.g. pindolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods of treating renal cancer, including renal cell carcinoma, using bezafibrate are disclosed herein. Bezafibrate can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.

## Claims

### Claim 1

A method for the treatment of renal cell carcinoma in a patient, the method comprising administering to said patient bezafibrate, or a pharmaceutically acceptable salt or prodrug thereof, in an amount effective to treat renal cell carcinoma.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the renal cell carcinoma comprises treat conventional (clear-cell) renal cell carcinoma, papillary renal cell-carcinoma, chromophobe renal carcinoma, onco-cytoma, or collecting-duct carcinoma.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the renal cell carcinoma comprises Stage I, Stage II, Stage III or Stage IV renal cell carcinoma.

### Claim 4 (depends on 1)

The method according to claim 1, wherein bezafibrate is administered in combination with at least one other cancer therapy.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the additional cancer therapy comprises surgery, chemotherapy, immunotherapy, or ionizing radiation.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the additional cancer therapy comprises administering at least one additional agent comprising a nucleoside analogue, antifolate, antimetabolite, topoisomerase I inhibitor, anthracycline, podophyllotoxin, taxanes, vinca alkaloid, alkylating agent, platinum compound, proteasome inhibitor, nitrogen mustards, oestrogen analogue, monoclonal antibody, tyrosine kinase inhibitor, mTOR inhibitor, retinoid, immunomodulatory agent, histone deacetylase inhibitor, or other kinase inhibitor.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the at least one additional agent comprises bevacizumab, axitinib, sorafenib, sunitinib, everolimus, temsirolimus, pazopanib, or lenvatinib.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the at least one additional agent comprises sunitinib.

### Claim 9 (depends on 6)

The method according to claim 6, wherein the at least one additional agent is administered simultaneously with bezafibrate.

### Claim 10 (depends on 6)

The method according to claim 6, wherein the at least one additional agent is administered sequentially with bezafibrate.

### Claim 11 (depends on 6)

The method according to claim 6, wherein the at least one additional agent is administered separately from bezafibrate.

### Claim 12 (depends on 4)

The method according to claim 4, wherein the bezafibrate is administered prior to treatment with ionizing radiation

### Claim 13 (depends on 4)

The method according to claim 4, wherein the bezafibrate is administered subsequent to treatment with ionizing radiation

### Claim 14 (depends on 4)

The method according to claim 4, wherein the bezafibrate is administered prior to surgical treatment for renal cell carcinoma.

### Claim 15 (depends on 4)

The method according to claim 4, wherein the bezafibrate is administered subsequent to surgical treatment for renal cell carcinoma.

### Claim 16

A pharmaceutical composition comprising bezafibrate and at least one additional renal cell carcinoma therapeutic agent.

### Claim 17

A kit comprising bezafibrate and at least one additional renal cell carcinoma therapeutic agent.

### Claim 18 (depends on 17)

The kit according to claim 17, wherein the bezafibrate is provided in a pharmaceutical composition suitable for oral administration.

### Claim 19 (depends on 17)

The kit according to claim 17, wherein the bezafibrate is provided in a pharmaceutical composition suitable for parenteral administration.

### Claim 20 (depends on 17)

The kit according to claim 17, wherein the bezafibrate and at least one additional therapeutic agent are provided in separate pharmaceutical compositions.
